ABOUT OPNA BIO
Opna Bio is a clinical stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company was founded to develop drugs aimed at disrupting the actions of an unprecedented new cancer target – fragile-X multifunctional RNA-binding protein (FMRP).
The role of FMRP in cancer was elucidated in the laboratory of Dr. Douglas Hanahan, co-founder of Opna Bio, and co-author of the seminal “Hallmarks of Cancer” series, which proposed a set of traits commonly acquired by human cancer cells and crucial for the formation of malignant tumors.
Core Programs
Opna Bio is focused on three core programs which address different hallmarks of cancer. In addition to its discovery-stage FMRP program, Opna Bio is developing OPN-2853, a differentiated BET Bromodomain inhibitor, and OPN-6602, a best-in-class EP300/CBP inhibitor. OPN-2853 is currently in development in patients with myelofibrosis in combination with ruxolitinib. OPN-6602 is currently in Phase 1 clinical development for the treatment of multiple myeloma patients.
View Pipeline
